Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for wome…
$1.96+1.03%
报价 2026-11-13
市值
$19.6M
EV
$-3.5M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -85.6%
$1.75$13.57
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ATOSAtossa Therapeutics, Inc. | $19.6M | +1.0% | +765.1% | 0% | – | – | – | |
| IMMXImmix Biopharma, Inc. | $657.1M | -2.9% | +72.9% | 0% | – | – | – | |
| SRZNSurrozen, Inc. | $236.4M | -0.2% | +178.3% | 99.4% | – | – | – | |
| GLSIGreenwich LifeSciences, Inc. | $219.3M | -2.2% | – | 0% | – | – | – | |
| WHWKWhitehawk Therapeutics Inc | $180.6M | -0.3% | +23.9% | 0% | – | – | – | |
| COYACoya Therapeutics, Inc. | $73.4M | -4.3% | -61.0% | 99.9% | – | – | – | |
| CGTXCognition Therapeutics, Inc. | $64.6M | +0.5% | +14.4% | 0% | – | – | – | |
| CLNNClene Inc. | $56.4M | -2.0% | +100.0% | -80.7% | – | – | – | |
| TILInstil Bio, Inc. | $41.2M | -2.6% | +2.6% | 0% | – | – | – | |
| 同行中位数 | – | – | +23.9% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。